Hattori Aritoshi, Matsunaga Takeshi, Fukui Mariko, Takamochi Kazuya, Suzuki Kenji
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Eur J Cardiothorac Surg. 2022 Jan 24;61(2):249-256. doi: 10.1093/ejcts/ezab436.
We evaluated the oncological role of a ground-glass opacity (GGO) component in hypermetabolic lung adenocarcinoma with a high maximum standardized uptake value.
Between 2008 and 2017, we retrospectively reviewed the data of surgically resected clinically node-negative lung adenocarcinomas with a hypermetabolic activity. Furthermore, they were classified based on the presence of GGO. The prognostic significance of a GGO in hypermetabolic tumours was evaluated using the Cox proportional-hazards model. The overall survival (OS) was estimated by the Kaplan-Meier method using a log-rank test.
Of the 1134 surgically resected clinically node-negative lung adenocarcinoma, 603 cases with hypermetabolic activity (maximum standardized uptake value ≥3.0 mg/dl) were evaluated. Among them, there were 120 (20%) cases in the With GGO group and 483 (80%) in the Solid group. The 5-year OS of patients with hypermetabolic lung adenocarcinoma was significantly different between the With GGO and Solid groups (83.1% vs 59.4%, P < 0.001). After stratifying by the presence of GGO, maximum standardized uptake value and maximum tumour size were independently significant prognosticators in the Solid group by multivariable analysis; however, no clinical factors were associated with survival among the With GGO group. The 5-year OS was favourable despite the solid component size among the With GGO group (T1a + T1b: 85.5%, T1c: 80.0%, T2a or more: 84.2%, P = 0.904). For the Solid group, survival diminished drastically with increasing tumour size (T1a + T1b: 68.7%, T1c: 62.8%, T2a or more: 48.0%, P < 0.001).
The prognosis of lung adenocarcinoma with GGO was favourable even in hypermetabolic tumours. Accordingly, the presence of GGO should be considered as an important parameter in the next clinical T classification.
我们评估了具有高最大标准化摄取值的代谢活跃型肺腺癌中磨玻璃影(GGO)成分的肿瘤学作用。
2008年至2017年期间,我们回顾性分析了手术切除的临床淋巴结阴性且代谢活跃的肺腺癌数据。此外,根据是否存在GGO对其进行分类。使用Cox比例风险模型评估GGO在代谢活跃型肿瘤中的预后意义。采用Kaplan-Meier法和对数秩检验估计总生存期(OS)。
在1134例手术切除的临床淋巴结阴性肺腺癌中,评估了603例代谢活跃(最大标准化摄取值≥3.0mg/dl)的病例。其中,GGO组有120例(20%),实性组有483例(80%)。GGO组和实性组代谢活跃型肺腺癌患者的5年OS有显著差异(83.1%对59.4%,P<0.001)。按GGO的存在进行分层后,多变量分析显示最大标准化摄取值和最大肿瘤大小在实性组中是独立的显著预后因素;然而,GGO组中没有临床因素与生存相关。尽管GGO组中有实性成分,但5年OS良好(T1a + T1b:85.5%,T1c:80.0%,T2a或更大:84.2%,P = 0.904)。对于实性组,随着肿瘤大小增加生存率急剧下降(T1a + T1b:68.7%,T1c:62.8%,T2a或更大:48.0%,P<0.001)。
即使在代谢活跃型肿瘤中,伴有GGO的肺腺癌预后也良好。因此,GGO的存在应被视为下一次临床T分类中的一个重要参数。